Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00657748
Other study ID # P070803
Secondary ID
Status Withdrawn
Phase Phase 2
First received April 9, 2008
Last updated April 20, 2015
Start date September 2009
Est. completion date January 2011

Study information

Verified date April 2015
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

The aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with Canavan Disease.


Description:

Canavan Disease is an autosomal recessive devastating demyelinating disease caused by a deficiency in Aspartoacylase (ASPA) enzyme. There is no available treatment. ASPA deficiency leads to:- the accumulation of high levels of N-acetylaspartate (NAA), involved in myelin degeneration and epilepsy;- the deficient synthesis of acetate in oligodendrocytes, that could impair CNS myelination.Lithium administration induces a decrease in NAA in the brain of the tremor rats (animal model for CD) and in one patient (JANSON, 2005). On the other hand, administration of acetate could improve myelination in Canavan patients.For this reason, we propose to combine both treatments: Lithium Gluconate and Glyceryl Triacetate (GTA). Eighteen patients, aged 1 to 15 years, will receive oral GTA or Lithium during 4 months, then both treatment in association during 6 months. Patients will be sequentially evaluated up to the end of the treatment and 2 months thereafter for:-tolerance of the therapy (careful monitoring of clinical and biological parameters).- efficacy of the therapy on clinical, biological and radiological parameters. Particularly, we will evaluate using MRI-spectroscopy and CSF samples the decrease in NAA and increase in acetate levels in the brain.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2011
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 15 Years
Eligibility Inclusion Criteria:

- Clinical and biochemical diagnosis of Canavan disease

Exclusion Criteria:

- Renal disease

- Thyroid disease

- Cardiac disease

- Impossibility to perform brain MRI

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris European Leukodystrophy Association

References & Publications (4)

Baslow MH, Kitada K, Suckow RF, Hungund BL, Serikawa T. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Neurochem Res. 2002 May;27(5):403-6. — View Citation

Janson CG, Assadi M, Francis J, Bilaniuk L, Shera D, Leone P. Lithium citrate for Canavan disease. Pediatr Neurol. 2005 Oct;33(4):235-43. — View Citation

Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Ac — View Citation

Mathew R, Arun P, Madhavarao CN, Moffett JR, Namboodiri MA. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther. 2005 O — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome will be a decrease of the NAA peak (> 20%) or the appearance of an acetate peak at the end of the treatment (10 months), using spectroscopy-MRI. 10 months Yes
Secondary Secondary outcomes will be assessed at 10 months (end of the treatment): -Improvement of neuromotor performances (GMFM and Mullen scales), spasticity, and neurological severity 10 months Yes
Secondary -Improvement of epilepsy (number of seizures) 10 months Yes
Secondary -Decrease in NAA and increase in acetate contents in fluids (CSF, plasma, urine). 10 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04998396 - A Study of AAV9 Gene Therapy in Participants With Canavan Disease Phase 1/Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT04126005 - Natural History Study of Patients With Canavan Disease
Completed NCT02851563 - A Natural History Study of Canavan Disease
Recruiting NCT00724802 - Oral Glyceryl Triacetate (GTA) in Newborns With Canavan N/A
Completed NCT01999257 - Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent. N/A
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04833907 - rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease Phase 1/Phase 2
No longer available NCT05317780 - Canavan-Single Patient IND